Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study

por Någård, Mats, Singh, Bhupinder, Boulton, David W
Publicado 2020

Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults

por Någård, Mats, Kramer, William G, Boulton, David W
Publicado 2020

A Literature Review of Changes in Phase II Drug-Metabolizing Enzyme and Drug Transporter Expression during Pregnancy

por Gong, Christine, Bertagnolli, Lynn N., Boulton, David W., Coppola, Paola
Publicado 2023

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans

por Lu, Yasong, Griffen, Steven C., Boulton, David W., Leil, Tarek A.
Publicado 2014

A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug–Drug Interactions with Orally Administered Medications

por Patel, Divya, Bertz, Richard, Ren, Song, Boulton, David W., Någård, Mats
Publicado 2019

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model

por Sokolov, Victor, Yakovleva, Tatiana, Penland, Robert C., Boulton, David W., Tang, Weifeng
Publicado 2023

Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes

por Jo, Heeseung, Pilla Reddy, Venkatesh, Parkinson, Joanna, Boulton, David W., Tang, Weifeng
Publicado 2021

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus

por Naagaard, M. Daniel, Chang, Roy, Någård, Mats, Tang, Weifeng, Boulton, David W.
Publicado 2022

Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects

por Wilcox, Christopher S., Shen, Wen, Boulton, David W., Leslie, Bruce R., Griffen, Steven C.
Publicado 2018

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin

por Butrovich, Morgan A., Tang, Weifeng, Boulton, David W., Nolin, Thomas D., Sharma, Pradeep
Publicado 2022

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes

por Sokolov, Victor, Yakovleva, Tatiana, Stolbov, Leonid, Penland, Robert C., Boulton, David, Parkinson, Joanna, Tang, Weifeng
Publicado 2023

Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus

por Parkinson, Joanna, Tang, Weifeng, Åstrand, Magnus, Melin, Johanna, Ekholm, Ella, Hamrén, Bengt, Boulton, David W.
Publicado 2019

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole

por Patel, Chirag G, Li, Li, Girgis, Suzette, Kornhauser, David M, Frevert, Ernest U, Boulton, David W
Publicado 2011

Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitu...

por Sokolov, Victor, Yakovleva, Tatiana, Ueda, Shinya, Parkinson, Joanna, Boulton, David W., Penland, Robert C., Tang, Weifeng
Publicado 2018

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus

por Melin, Johanna, Tang, Weifeng, Rekić, Dinko, Hamrén, Bengt, Penland, Robert C., Boulton, David W., Parkinson, Joanna
Publicado 2022

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab

por Tang, Weifeng, Tummala, Raj, Almquist, Joachim, Hwang, Michael, White, Wendy I., Boulton, David W., MacDonald, Alexander
Publicado 2023

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

por Pollack, Pia S., Chadwick, Kristina D., Smith, David M., Billger, Martin, Hirshberg, Boaz, Iqbal, Nayyar, Boulton, David W.
Publicado 2017

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

por Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L.
Publicado 2019

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects

por Vakkalagadda, Blisse, Vetter, Marion L., Rana, Jignasa, Smith, Charles H., Huang, Jian, Karkas, Jennifer, Boulton, David W., LaCreta, Frank
Publicado 2016

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes

por Watada, Hirotaka, Shiramoto, Masanari, Ueda, Shinya, Tang, Weifeng, Asano, Michiko, Thorén, Fredrik, Kim, Hyosung, Yajima, Toshitaka, Boulton, David W., Araki, Eiichi
Publicado 2018